Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free AKTX Stock Alerts

Akari Therapeutics (AKTX) Competitors

Akari Therapeutics logo
$9.76 -0.30 (-2.98%)
Closing price 09/25/2026 03:59 PM Eastern
Extended Trading
$10.10 +0.35 (+3.53%)
As of 09/25/2026 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AKTX vs. ACRV, TELO, SERA, KLRS, and PMVP

Should you buy Akari Therapeutics stock or one of its competitors? Akari Therapeutics's main competitors and comparable companies include Acrivon Therapeutics (ACRV), Telomir Pharmaceuticals (TELO), Sera Prognostics (SERA), Kalaris Therapeutics (KLRS), and PMV Pharmaceuticals (PMVP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akari Therapeutics compare to Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ:ACRV) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Acrivon Therapeutics' return on equity of -70.14% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Acrivon TherapeuticsN/A -70.14% -61.60%
Akari Therapeutics N/A -147.45%-74.70%

Acrivon Therapeutics presently has a consensus price target of $13.50, indicating a potential upside of 542.86%. Akari Therapeutics has a consensus price target of $32.33, indicating a potential upside of 231.28%. Given Acrivon Therapeutics' higher probable upside, research analysts clearly believe Acrivon Therapeutics is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acrivon Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Acrivon Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

In the previous week, Acrivon Therapeutics and Acrivon Therapeutics both had 3 articles in the media. Akari Therapeutics' average media sentiment score of 0.94 beat Acrivon Therapeutics' score of 0.12 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Acrivon Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

71.6% of Acrivon Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 10.5% of Acrivon Therapeutics shares are owned by company insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acrivon TherapeuticsN/AN/A-$77.90M-$1.88N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

Summary

Acrivon Therapeutics and Akari Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Akari Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Telomir Pharmaceuticals currently has a consensus target price of $4.00, suggesting a potential upside of 225.20%. Akari Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 231.28%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Telomir Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Telomir Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

In the previous week, Akari Therapeutics had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Telomir Pharmaceuticals. Akari Therapeutics' average media sentiment score of 0.94 beat Telomir Pharmaceuticals' score of -0.11 indicating that Akari Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Telomir Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Telomir Pharmaceuticals has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Telomir PharmaceuticalsN/AN/A-$10.41M-$0.91N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

Telomir Pharmaceuticals' return on equity of -102.70% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Telomir PharmaceuticalsN/A -102.70% -90.75%
Akari Therapeutics N/A -147.45%-74.70%

5.1% of Akari Therapeutics shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Akari Therapeutics beats Telomir Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Sera Prognostics?

Akari Therapeutics (NASDAQ:AKTX) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Akari Therapeutics has higher earnings, but lower revenue than Sera Prognostics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.30MN/AN/A
Sera Prognostics$70K1,149.66-$31.93M-$0.67N/A

In the previous week, Akari Therapeutics and Akari Therapeutics both had 3 articles in the media. Akari Therapeutics' average media sentiment score of 0.94 beat Sera Prognostics' score of 0.89 indicating that Akari Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sera Prognostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Akari Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 231.28%. Sera Prognostics has a consensus target price of $5.50, suggesting a potential upside of 169.61%. Given Akari Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than Sera Prognostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Sera Prognostics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

Akari Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by company insiders. Comparatively, 11.3% of Sera Prognostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Akari Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A -147.45% -74.70%
Sera Prognostics -47,475.72%-46.71%-34.06%

Summary

Akari Therapeutics beats Sera Prognostics on 8 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

In the previous week, Akari Therapeutics had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.42 beat Akari Therapeutics' score of 0.94 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kalaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Akari Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kalaris Therapeutics has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kalaris TherapeuticsN/AN/A-$43.44M-$2.02N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

66.1% of Kalaris Therapeutics shares are owned by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are owned by institutional investors. 68.1% of Kalaris Therapeutics shares are owned by insiders. Comparatively, 32.2% of Akari Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kalaris Therapeutics' return on equity of -71.71% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Kalaris TherapeuticsN/A -71.71% -42.95%
Akari Therapeutics N/A -147.45%-74.70%

Kalaris Therapeutics presently has a consensus target price of $18.75, suggesting a potential upside of 542.12%. Akari Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 231.28%. Given Kalaris Therapeutics' higher probable upside, analysts plainly believe Kalaris Therapeutics is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kalaris Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Kalaris Therapeutics beats Akari Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Akari Therapeutics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Akari Therapeutics (NASDAQ:AKTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of Akari Therapeutics shares are held by institutional investors. 10.2% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 32.2% of Akari Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PMV Pharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, Akari Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMV PharmaceuticalsN/AN/A-$77.74M-$1.42N/A
Akari TherapeuticsN/AN/A-$17.30MN/AN/A

PMV Pharmaceuticals' return on equity of -78.11% beat Akari Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PMV PharmaceuticalsN/A -78.11% -70.13%
Akari Therapeutics N/A -147.45%-74.70%

In the previous week, Akari Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 3 mentions for Akari Therapeutics and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.82 beat Akari Therapeutics' score of 0.94 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
PMV Pharmaceuticals Very Positive
Akari Therapeutics Positive

PMV Pharmaceuticals currently has a consensus target price of $4.33, suggesting a potential upside of 225.81%. Akari Therapeutics has a consensus target price of $32.33, suggesting a potential upside of 231.28%. Given Akari Therapeutics' higher possible upside, analysts clearly believe Akari Therapeutics is more favorable than PMV Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PMV Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Akari Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Akari Therapeutics beats PMV Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Akari Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKTX vs. The Competition

Export
MetricAkari TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$18.99M$3.94B$7.33B$13.17B
Dividend YieldN/A3.63%2.52%14.03%
P/E RatioN/A14.15275.8225.78
Price / SalesN/A1,438.70649.6092.85
Price / CashN/A120.9179.5252.89
Price / Book0.3915.2810.446.30
Net Income-$17.30M-$22.90M$3.51B$360.35M
7 Day Performance6.55%-2.94%-1.31%-0.23%
1 Month Performance8.32%-8.80%-4.61%-4.16%
1 Year Performance-74.85%28.99%15.01%4.58%

Akari Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AKTX
Akari Therapeutics
3.6272 of 5 stars		$9.76
-3.0%		$32.33
+231.3%		-74.8%$18.99MN/AN/A5
ACRV
Acrivon Therapeutics
2.7501 of 5 stars		$1.83
-6.6%		$13.50
+637.7%		+26.5%$83.99MN/AN/A58
TELO
Telomir Pharmaceuticals
1.9846 of 5 stars		$1.17
flat		N/A-11.5%$80.47MN/AN/A1
SERA
Sera Prognostics
3.1037 of 5 stars		$1.99
-0.5%		$5.50
+176.4%		-34.0%$78.90M$80KN/A120
KLRS
Kalaris Therapeutics
3.5922 of 5 stars		$3.20
-3.0%		$18.75
+485.9%		-48.0%$78.56MN/AN/A110

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AKTX) was last updated on 9/27/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
100% overnight gains?
Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...
The Oxford Club | Sponsoredtc pixel